ARTICLE | Finance
Fulcrum’s genetic levers
Why Foresite led an $80M series B round for gene regulation play Fulcrum.
September 5, 2018 11:04 AM UTC
Fulcrum Therapeutics Inc.’s ability to identify targets for genetic disease drivers using bioinformatics prompted Foresite Capital to lead the company’s untranched $80 million series B round.
Fellow new investors Fidelity, 6 Dimensions Capital, Casdin Capital, Sanofi Ventures, Section 32, NS Investments, entities affiliated with Leerink Partners and undisclosed institutional investors also participated. ...
BCIQ Target Profiles